Antia U, Tingle MD, Russell BR (2009) Metabolic interactions with piperazine-based ‘party pill’ drugs. J Pharm Pharmacol 61:877–882

Article  CAS  PubMed  Google Scholar 

Antia U, Tingle MD, Russell BR (2010) Validation of an LC–MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci (in press)

Auerbach SB, Kamalakannan N, Rutter JJ (1990) TFMPP and RU24969 enhance serotonin release from rat hippocampus. Eur J Pharmacol 190:51–57

Article  CAS  PubMed  Google Scholar 

Auerbach SB, Rutter JJ, Juliano PJ (1991) Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology 30:307–311

Article  CAS  PubMed  Google Scholar 

Baumann MH, Mash DC, Staley JK (1995) The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 6:2150–2152

Article  CAS  PubMed  Google Scholar 

Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘ecstasy’). Neuropsychopharmacology 30:550–560

Article  CAS  PubMed  Google Scholar 

Cloëz-Tayarani I, Harel-Dupas C, Fillion G (1992) Inhibition of [3H] gamma-aminobutyric acid release from guinea-pig hippocampal synaptosomes by serotonergic agents. Fundam Clin Pharmacol 6:333–341

Article  PubMed  Google Scholar 

Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors. J Pharmacol Exp Ther 242:652–657

Google Scholar 

Cunningham KA, Carroll BA, Appel JB (1986) Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of d-lysergic acid diethylamide (LSD) and 1-(m-trifluoromethylphenyl) piperazine (TFMPP). Psychopharmacology 89:134–135

Article  CAS  PubMed  Google Scholar 

Deneau G, Yanagita T, Seevers MH (1969) Self-administration of psychoactive substances by the monkey. Psychopharmacologia 16:30–48

Article  CAS  PubMed  Google Scholar 

Erowid Piperazine Vault (2009) Erowid experience vaults: piperazine reports. http://www.erowid.org/chemicals/piperazines

Evans SN (2007) The role of estradiol and progesterone in modulating the subjective effects of stimulants in humans. Exp Clin Psychopharmacol 15:418–426

Article  CAS  PubMed  Google Scholar 

Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A (2005) Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77:161–168

Article  CAS  PubMed  Google Scholar 

Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochemical Pharmacology 75:17–33

Article  CAS  PubMed  Google Scholar 

FDA (1997) US Food and Drug Administration postmarket drug safety information for patients and providers: FDA announces withdrawal of fenfluramine and dexfenfluramine. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm

FDA (2009) US Food and Drug Administration. http://www.fda.gov

Folstein MF, Luria R (1973) Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3:479–486

Article  CAS  PubMed  Google Scholar 

Foltin RW, Fischman MW (1991) Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28:3–48

Article  CAS  PubMed  Google Scholar 

Garattini S, Borroni E, Mennini T, Samanin R (1978) Differences and similarities among anorectic agents. In: Garattini S, Samanin R (eds) Central mechanisms of anorectic drugs. Raven, New York, pp 127–143

Google Scholar 

Griffith JD, Nutt JG, Jasinski DR (1975) A comparison of fenfluramine and amphetamine in man. Clin Pharmacol Ther 18:563–570

CAS  PubMed  Google Scholar 

Grotewiel MS, Chu H, Sanders-Bush E (1994) m-Chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 271:1122–1126

CAS  PubMed  Google Scholar 

Haertzen CA, Hill HE, Belleville RE (1963) Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 4:155–166

Article  CAS  PubMed  Google Scholar 

Hamik A, Peroutka SJ (1989) 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569–575

Article  CAS  PubMed  Google Scholar 

Herndon L, Pierson ME, Glennon RA (1992) Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl) piperazine. Pharmacol Biochem Behav 43:739–748

Article  CAS  PubMed  Google Scholar 

Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139–1166

Article  CAS  PubMed  Google Scholar 

Kennett GA, Curzon G (1988) Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors. Psychopharmacology 96:93–100

Article  CAS  PubMed  Google Scholar 

Koob GF (1992) Neuronal mechanisms of drug reinforcement. Ann N Y Acad Sci 654:171–191

Article  CAS  PubMed  Google Scholar 

Lin JC, Bangs N, Lee HS, Kydd RR, Russell BR (2009) Determining the subjective and physiological effects of BZP on human females. Psychopharmacology 207:439–446

Article  CAS  PubMed  Google Scholar 

Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258

CAS  PubMed  Google Scholar 

McKenney JD, Glennon RA (1986) TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol Biochem Behav 24:43–47

Article  CAS  PubMed  Google Scholar 

McNair DM, Heuchert JWP, Shilony E (2003) Research with the Profile of Mood States (POMS) 1964–2002: a comprehensive bibliography. MHC, Toronto, pp 7–8

Google Scholar 

Miranda F, Orozco G, Velazquez-Martinez DN (2002) Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist. Behav Pharmacol 13:303–311

CAS  PubMed  Google Scholar 

Misuse of Drugs Amendment Act (2008) Classification of BZP Amendment Bill: Bill 146-2, New Zealand

Robertson DW, Bloomquist W, Wong DT, Cohen ML (1992) mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. Life Sci 50:599–605

Article  CAS  PubMed  Google Scholar 

Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100:869–875

CAS  PubMed  Google Scholar 

Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41

Article  CAS  PubMed  Google Scholar 

Schechter MD (1988) Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation. Pharmacol Biochem Behav 31:53–57

Article  CAS  PubMed  Google Scholar 

Schoeffter P, Hoyer D (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol 339:675–683

Article  CAS  PubMed  Google Scholar 

Sheridan J, Butler R (2007) Legal party pills and their use by young people in New Zealand: a qualitative study. Final report of findings (revised June 2007). University of Auckland, Auckland

Google Scholar 

Sheridan J, Butler R, Wilkins C, Russell B (2007) Legal piperazine-containing party pills—a new trend in substance misuse. Drug Alcohol Rev 26:335–343

Article  PubMed  Google Scholar 

Tancer M, Johanson C-E (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72:33–44

Article  CAS  PubMed  Google Scholar 

The UK Home Office (2009) Control of ‘legal highs’ including GBL, BZP, synthetic cannabinoids and others. http://drugs.homeoffice.gov.uk/news-events/latest-news/control-of-legal-highs-dec09.html

US Drug Enforcement Administration, Department of Justice (2002) Schedules of controlled substances: temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into Schedule I. Fed Regist 67:59161–59162

Google Scholar 

Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J (2006) Legal party pill use in New Zealand: prevalence of use, availability, health harms and ‘gateway effects’ of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP). Centre for Social and Health Outcomes Research and Evaluation, Massey University, Auckland

Google Scholar 

Zacny JP, de Wit H (1989) Effects of food deprivation on subjective responses to d-amphetamine in humans. Pharmacol Biochem Behav 34:791–795

Article  CAS  PubMed  Google Scholar